Comparison of immunogenicity and reactogenicity of a measles, mumps and rubella (MMR) vaccine in German children vaccinated at 9–11, 12–14 or 15–17 months of age☆☆Results of this study were presented at the annual meetings of the German Society for Paediatrics and Adolescent Medicine, September 1997, Vienna (Austria) and the German Society for Paediatric Infectious Diseases, November 1997, Berlin (Germany)
| Autor: | Ulrich Heininger, J. Klinge, K. Korn, S. Lugauer, Klemens Stehr |
|---|---|
| Rok vydání: | 2000 |
| Předmět: |
Pediatrics
medicine.medical_specialty Reactogenicity General Veterinary General Immunology and Microbiology biology Measles-Mumps-Rubella Vaccine business.industry Public Health Environmental and Occupational Health MMR vaccine medicine.disease biology.organism_classification Rubella Measles Measles virus Vaccination Infectious Diseases Immunology medicine Molecular Medicine Seroconversion business |
| Zdroj: | Vaccine. 18:3134-3140 |
| ISSN: | 0264-410X |
| Popis: | Children aged 9-11, 12-14 or 15-17 months, respectively were vaccinated with a measles, mumps and rubella (MMR) vaccine and serum antibody responses and reactogenicity were compared. The data of 118 children could be analysed (group 1=9-11 months, n=46; group 2=12-14 months, n=29, group 3, 15-17 months, n=43). The only significant difference observed was for seroconversion against measles virus between group 1 and group 3 (84.8% vs 100%, p=0.012). No serious adverse events were reported. Local side reactions were mild, infrequent and independent of age. Immunisation against MMR is safe and effective even when administered before the currently recommended age of 12 months. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect